Tissue Repair & Recovery

KPV

Also known as Lysine-Proline-Valine · α-MSH (11-13) · alpha-MSH C-terminal tripeptide

PreliminaryOralTopicalSubcutaneous injectionNot FDA-approved for any indication. Used in some compounded formulations; was among peptides removed from the FDA interim 503A Category 2 bulks list in April 2026 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review beginning July 2026.

KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research suggests it can enter cells and dampen inflammatory signaling (for example, reducing NF-κB activity), in part independent of classic melanocortin receptors. Most available data come from animal models of inflammatory conditions such as colitis, dermatitis, and corneal wounds; controlled human clinical trials are lacking.

Studied / used for

Studied in animal models of gut inflammation (colitis)
Investigated for skin inflammation and wound healing in preclinical models
Studied for anti-inflammatory signaling (NF-κB modulation)
Studied in research contexts related to inflammatory bowel and skin conditions

Commonly reported side effects

Injection-site reactions reported with subcutaneous use
Limited human safety data overall
Generally reported as well tolerated in available research

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds